Drug
Imetelstat clinical trials
Also written GRN163L.
- studies test it
- 25
- open now
- 3
- in phase 3
- 2
- first study started
- 2005
Keep track of what changes. Save the imetelstat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- GRN163L
- 15
Studies by the year they started
25 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 11
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 9
Geron Corporation (15) · Children's Oncology Group (3) · GCP-Service International West GmbH (1) · Indiana University (1) · M.D. Anderson Cancer Center (1) · Douglas Tremblay (1) · Pediatric Brain Tumor Consortium (1) · NCIC Clinical Trials Group (1)
Often tested with
Tested in the same studies.
Ruxolitinib (1) · Cytarabine (1) · Fludarabine (1) · Azacitidine (1)
Studies
Open first, then newest update. How each study uses imetelstat is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyRecruitingPhase 1Children's Oncology GroupNCT06247787Written as Imetelstat
- Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative NeoplasmsNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07549451Written as Imetelstat
- Imetelstat Combinations in Relapsed AMLRecruitingPhase 1Douglas TremblayNCT07320235Written as Imetelstat
- Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyCompletedPhase 2GCP-Service International West GmbHNCT05583552Written as Imetelstat sodium
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisActive, not recruitingPhase 1Geron CorporationNCT05371964Written as Imetelstat sodium
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Active, not recruitingPhase 2/3Geron CorporationNCT02598661Written as Imetelstat Sodium
- A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentActive, not recruitingPhase 3Geron CorporationNCT04576156Written as Imetelstat
- Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaCompletedPhase 2Geron CorporationNCT01242930Written as Imetelstat (7.5 mg/kg)
- Imetelstat Sodium in Treating Participants With Primary or Secondary MyelofibrosisCompletedPhase 2Geron CorporationNCT01731951Written as Imetelstat
- Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) InhibitorCompletedPhase 2Geron CorporationNCT02426086Written as Imetelstat 4.7 mg/kg
- Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With NeuroblastomaWithdrawnPhase 1NCIC Clinical Trials GroupNCT01916187Written as Imetelstat
- Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid TumorsWithdrawnPhase 2Children's Oncology GroupNCT02011126Written as Imetelstat Sodium
- Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain TumorsTerminatedPhase 2Pediatric Brain Tumor ConsortiumNCT01836549Written as imetelstat sodium
- Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia VeraCompletedPhase 2Geron CorporationNCT01243073Written as Imetelstat
- Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast CancerCompletedPhase 2Geron CorporationNCT01256762Written as Imetelstat sodium
- Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2Geron CorporationNCT01137968Written as imetelstat
- Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)CompletedPhase 1Geron CorporationNCT00124189Written as GRN163L
- Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed MyelomaCompletedPhase 1Geron CorporationNCT00718601Written as Imetelstat Sodium (GRN163L)
- Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple MyelomaCompletedPhase 1Geron CorporationNCT00594126Written as Imetelstat Sodium (GRN163L)
- Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor MalignanciesCompletedPhase 1Geron CorporationNCT00310895Written as Imetelstat Sodium (GRN163L)
Codes
What other systems call imetelstat · ClinicalTrials.gg INT005080
- MeSH (NLM) C519562imetelstatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) F60NE4XB53IMETELSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q21083935imetelstatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49084ImetelstatOne source FDA
- DrugBank DB14909One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C519562 | imetelstat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F60NE4XB53 | IMETELSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21083935 | imetelstat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49084 | Imetelstat | One source FDA |
| DrugBank | DB14909 | — | One source Wikidata |
Also registered as imetelstat sodium (UNII 2AW48LAZ4I).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.